Mexazolam API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Mexazolam API 31868-18-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Mexazolam. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Mexazolam
- Synonyms:
- Mexazolamum
- Cas Number:
- 31868-18-5
- DrugBank number:
- DB15489
- Unique Ingredient Identifier:
- S5969B6237
General Description:
Mexazolam, identified by CAS number 31868-18-5, is a notable compound with significant therapeutic applications. Mexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions. Mexazolam's structure is similar to that of other benzodiazepines such as and . The use of benzodiazepines in the treatment of anxiety is generally a second line measure.
Indications:
This drug is primarily indicated for: Mexazolam is indicated for the treatment of anxiety with or without psychoneurotic conditions. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Mexazolam undergoes metabolic processing primarily in: Mexazolam is rapidly metabolized to the active metabolites chloronordiazepam and chloroxazepam. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Mexazolam are crucial for its therapeutic efficacy: The active metabolite chloronordiazepam has a Tmax of 1-2h. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Mexazolam is an important consideration for its dosing schedule: Mexazolam follows a 2 compartment model with a first half life of 1.4h and a second half life of 76h. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Mexazolam exhibits a strong affinity for binding with plasma proteins: Mexazolam is >90% protein bound in plasma. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Mexazolam from the body primarily occurs through: Mexazolam is mainly eliminated in the bile and feces, with <10% eliminated as metabolites in the urine. >50% of a dose of mexazolam is eliminated as the metabolite chloroxazepam. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Mechanism of Action:
Mexazolam functions by: Mexazolam is a benzodiazepine that binds to benzodiazepine-type receptors, inhibiting gamma-aminobutyric acid. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Mexazolam is categorized under the following therapeutic classes: Anti-Anxiety Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Nervous System, Psycholeptics. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Mexazolam is a type of Anti-anxiety
The Anti-anxiety category in the pharmaceutical API (Active Pharmaceutical Ingredient) market refers to a group of substances specifically developed to alleviate symptoms associated with anxiety disorders. Anxiety disorders are mental health conditions characterized by excessive worry, fear, and unease that can significantly impact daily life.
Pharmaceutical APIs within the Anti-anxiety category work by modulating the activity of neurotransmitters in the brain, particularly gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter that helps regulate the excitability of neurons. By enhancing GABA's inhibitory effects, these APIs promote a calming effect, reducing anxiety symptoms.
Common Anti-anxiety APIs include benzodiazepines, such as alprazolam, diazepam, and lorazepam. These substances act as central nervous system depressants, inducing sedation and relaxation. Other APIs in this category include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and certain antihistamines.
Pharmaceutical companies develop and manufacture Anti-anxiety APIs to meet the growing demand for effective anxiety treatment options. These APIs are typically used as the active ingredient in the production of various anti-anxiety medications, such as tablets, capsules, or liquid formulations.
The market for Anti-anxiety APIs is influenced by factors such as increasing awareness about mental health, rising prevalence of anxiety disorders, and the growing demand for personalized treatment options. Regulatory compliance, quality control, and safety are crucial considerations in the development and production of these APIs to ensure efficacy and minimize potential side effects.
Overall, Anti-anxiety APIs play a vital role in the pharmaceutical industry by providing effective solutions for individuals struggling with anxiety disorders, enhancing their quality of life, and promoting overall well-being.
